Gelteq (GELS) Competitors $1.40 +0.05 (+3.70%) As of 09/26/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock GELS vs. RLMD, PDSB, ACRV, INMB, SONN, ICCC, ATNM, KPTI, ZIVO, and BTAIShould you be buying Gelteq stock or one of its competitors? The main competitors of Gelteq include Relmada Therapeutics (RLMD), PDS Biotechnology (PDSB), Acrivon Therapeutics (ACRV), INmune Bio (INMB), Sonnet BioTherapeutics (SONN), ImmuCell (ICCC), Actinium Pharmaceuticals (ATNM), Karyopharm Therapeutics (KPTI), ZIVO Bioscience (ZIVO), and BioXcel Therapeutics (BTAI). These companies are all part of the "pharmaceutical products" industry. Gelteq vs. Its Competitors Relmada Therapeutics PDS Biotechnology Acrivon Therapeutics INmune Bio Sonnet BioTherapeutics ImmuCell Actinium Pharmaceuticals Karyopharm Therapeutics ZIVO Bioscience BioXcel Therapeutics Relmada Therapeutics (NASDAQ:RLMD) and Gelteq (NASDAQ:GELS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability. Do insiders and institutionals hold more shares of RLMD or GELS? 45.2% of Relmada Therapeutics shares are held by institutional investors. 20.7% of Relmada Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has preferable earnings and valuation, RLMD or GELS? Gelteq has higher revenue and earnings than Relmada Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRelmada TherapeuticsN/AN/A-$79.98M-$2.22-0.82Gelteq$100K132.16-$2.33MN/AN/A Do analysts recommend RLMD or GELS? Relmada Therapeutics currently has a consensus target price of $1.00, suggesting a potential downside of 44.75%. Given Relmada Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Relmada Therapeutics is more favorable than Gelteq.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Relmada Therapeutics 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Gelteq 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor RLMD or GELS? In the previous week, Relmada Therapeutics had 3 more articles in the media than Gelteq. MarketBeat recorded 4 mentions for Relmada Therapeutics and 1 mentions for Gelteq. Gelteq's average media sentiment score of 1.89 beat Relmada Therapeutics' score of 1.11 indicating that Gelteq is being referred to more favorably in the news media. Company Overall Sentiment Relmada Therapeutics Positive Gelteq Very Positive Is RLMD or GELS more profitable? Gelteq's return on equity of 0.00% beat Relmada Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Relmada TherapeuticsN/A -223.17% -180.41% Gelteq N/A N/A N/A SummaryRelmada Therapeutics and Gelteq tied by winning 5 of the 10 factors compared between the two stocks. Get Gelteq News Delivered to You Automatically Sign up to receive the latest news and ratings for GELS and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GELS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GELS vs. The Competition Export to ExcelMetricGelteqMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.74M$3.07B$5.63B$10.32BDividend YieldN/A2.43%5.79%4.65%P/E RatioN/A21.1975.7526.14Price / Sales132.16412.68526.41121.04Price / CashN/A44.6837.1160.83Price / Book1.089.7412.416.36Net Income-$2.33M-$52.93M$3.29B$270.97M7 Day Performance3.70%3.89%1.27%0.34%1 Month Performance5.26%7.45%3.43%6.06%1 Year PerformanceN/A18.28%63.29%27.34% Gelteq Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GELSGelteqN/A$1.40+3.7%N/AN/A$12.74M$100K0.00N/APositive NewsGap UpRLMDRelmada Therapeutics2.8902 of 5 stars$1.65+9.3%$1.00-39.4%-44.8%$54.76MN/A-0.7410Positive NewsPDSBPDS Biotechnology1.947 of 5 stars$1.15flat$10.00+769.6%-67.4%$54.08MN/A-1.2520High Trading VolumeACRVAcrivon Therapeutics3.6369 of 5 stars$1.67+7.1%$15.00+798.2%-77.1%$52.53MN/A-0.7458Positive NewsINMBINmune Bio3.3769 of 5 stars$1.97+3.1%$18.40+834.0%-59.5%$52.36M$10K-0.7910Positive NewsSONNSonnet BioTherapeutics2.6498 of 5 stars$7.58+7.4%$20.00+163.9%-8.7%$51.77M$20K0.0010ICCCImmuCell1.3735 of 5 stars$5.70+0.9%N/A+67.0%$51.56M$28.27M30.0070Positive NewsGap DownATNMActinium Pharmaceuticals2.101 of 5 stars$1.65+2.5%$4.50+172.7%-10.1%$51.47MN/A-1.1930KPTIKaryopharm Therapeutics3.6941 of 5 stars$5.73-5.8%$34.00+493.4%-38.2%$49.69M$137.27M-0.39380ZIVOZIVO Bioscience0.0986 of 5 stars$13.00-2.3%N/A-15.4%$49.62M$15.85K-2.6610Gap UpBTAIBioXcel Therapeutics4.0358 of 5 stars$3.01+3.8%$39.75+1,220.6%-68.4%$48.19M$2.27M-0.2490Positive NewsGap Up Related Companies and Tools Related Companies Relmada Therapeutics Competitors PDS Biotechnology Competitors Acrivon Therapeutics Competitors INmune Bio Competitors Sonnet BioTherapeutics Competitors ImmuCell Competitors Actinium Pharmaceuticals Competitors Karyopharm Therapeutics Competitors ZIVO Bioscience Competitors BioXcel Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GELS) was last updated on 9/27/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gelteq Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Gelteq With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GELS Stock Alerts